Stegeman I, van Doorn S C, Mundt M W, Mallant-Hent R C, Bongers E, Elferink M A G, Fockens P, Stroobants A K, Bossuyt P M, Dekker E
Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands.
Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands.
Cancer Epidemiol. 2015 Jun;39(3):388-93. doi: 10.1016/j.canep.2015.03.012. Epub 2015 Apr 21.
The effectiveness of colorectal cancer screening programs based on the fecal immunochemical test (FIT) is influenced by program adherence during consecutive screening rounds. We aimed to evaluate the participation rate, yield, and interval cancers in a third round of biennial CRC screening using FIT and to compare those with the first and the second screening round.
A total of 3566 average-risk individuals aged 50-75 years were invited to participate in a third round of biennial FIT-based CRC screening. All FIT positives were recommended to undergo colonoscopy. We merged our data with the national cancer registry in the Netherlands to identify all non-screen-detected cancers in our cohort.
Of the invitees, 2142 (60%) returned the FIT in this third screening round, compared to 56% in the second round and 57% in the first round. Overall, 153 of the third-round participants (7.1%) had a positive FIT result, versus 7.9% in the second round and 8.1% in the first round (P=0.05). Of all FIT positives, 123 (80%) underwent colonoscopy. Within this group, 33 persons had advanced neoplasia. The predictive value of FIT positivity for advanced neoplasia was 27% (33/123), compared to 42% in the second round and 54% in the first round - a significant decline (P<0.01).
In an FIT-based screening program, participation rates remained stable over consecutive biennial screening rounds, while the FIT positivity rate and positive predictive value for advanced neoplasia gradually declined. Cancers in non-participants are significantly more advanced in staging than cancers in participants in the first round of screening.
基于粪便免疫化学检测(FIT)的结直肠癌筛查项目的有效性受连续筛查轮次中项目依从性的影响。我们旨在评估使用FIT进行的第三轮两年一次的结直肠癌筛查中的参与率、检出率和间隔期癌症,并将其与第一轮和第二轮筛查进行比较。
总共邀请了3566名年龄在50 - 75岁的平均风险个体参加第三轮两年一次的基于FIT的结直肠癌筛查。所有FIT检测呈阳性者均被建议进行结肠镜检查。我们将我们的数据与荷兰国家癌症登记处合并,以确定我们队列中所有未通过筛查检测出的癌症。
在受邀者中,2142人(60%)在第三轮筛查中返回了FIT检测结果,第二轮为56%,第一轮为57%。总体而言,第三轮参与者中有153人(7.1%)FIT检测结果呈阳性,第二轮为7.9%,第一轮为8.1%(P = 0.05)。在所有FIT检测呈阳性者中,123人(80%)接受了结肠镜检查。在这一组中,33人患有高级别瘤变。FIT检测阳性对高级别瘤变的预测价值为27%(33/123),第二轮为42%,第一轮为54%——显著下降(P < 0.01)。
在基于FIT的筛查项目中,连续两年一次的筛查轮次中参与率保持稳定,而FIT检测阳性率和对高级别瘤变的阳性预测价值逐渐下降。未参与者中的癌症分期比第一轮筛查参与者中的癌症分期明显更晚。